Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease ...

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.

Madam Goh, now 62, had thyroid eye disease (TED), a rare autoimmune disease in which the eye muscles and fatty tissue behind ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 ...

As previously announced, ACELYRIN held an End of Phase 2 (EOP2) meeting with the United States Food and Drug Administration (FDA) in Q3 2024 and gained alignment on the proposed LONGITUDE-1 and ...

Topline data were announced from the phase 3 THRIVE-2 study evaluating veligrotug in patients with chronic thyroid eye ...

Acelyrin (SLRN) announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease. In the newly announced ...

ACELYRIN, INC. (SLRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram ...